Neopterin on Admission to Intensive Care Unit

NCT05233267 | Recruiting

• 2 other identifiers: APHP2100832021-A02264-37
• Study Type: observational
• Target: 326
• Locations: 1 country
• Sites: 1

Brief Summary

For the last twenty years, the proportion of patients aged 80 years and more, hospitalized in intensive care (ICU) has been increasing. The question of the admission of an elderly patient in intensive care raises many medico-socio-economic questions. The general objective of geriatric management is to improve the survival of the patient by maintaining his autonomy. Before an invasive management, it is therefore important to assess which patients are capable of surviving in good conditions. Moreover, as intensive care resources are not extensible, it is important to rationalise the use of this type of care. To date, there are no reliable criteria for predicting which patients will benefit from ICU care. The use of a predictive biomarker, in addition to the existing scores which are not very effective in this population, could guide the intensive care physician in his decision which is generally made in the emergency. The hypothesis of the study is that neopterin measured on admission of the elderly patient to the ICU may improve prediction of survival without major loss of autonomy at 3 months. Acute stress induced by a serious pathology has a profound impact on the immune system via the activation of the neuroendocrine system and the production of endogenous cortisol. Usually, cortisol inhibits the production of pro-inflammatory cytokines such as interferon gamma (IFNg). Sometimes this inhibition is ineffective and leads to an intense pro-inflammatory state that is harmful to the body. Neopterin is produced by monocytes/macrophages under the influence of IFNg. It is associated with a poor prognosis in many diseases such as sepsis or cancer. In the comorbid elderly patient with an upper femoral fracture, the pre-operative neopterin level is predictive of one-year mortality and functional recovery. The hypothesis of the study is that neopterin measured on admission of the elderly patient to the ICU may improve prediction of survival without major loss of autonomy at 3 months. Each patient will be included on admission to the intensive care unit within a maximum of 24 hours (D0). Demographic data (age, sex), severity (IGSIII), comorbidity (CIRS), autonomy (ADL and IADL) and frailty (CFS) scores will be collected as well as the diagnosis at admission. Two additional tubes will be collected during the entry assessment (performed as part of usual care) at inclusion (D0) for neopterin and other biomarkers (4 ml dry tube and 10 ml lithium heparin tube). The blood tubes will be transferred to the research laboratory within 48 hours after sampling. The determination of neopterin, cytokines and oxidative stress biomarkers will be performed by an enzyme-linked immunosorbent assay (Neopterin ELISA Kit CE-IVD, Tecan laboratory) at the Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris). The assays will be performed at the end of the study, blinded to the patient's outcome, and the follow-up of the patients will be performed blinded to the results of the neopterin assay and the other markers. Patients will be followed up at 3 months from inclusion (M3). The follow-up data will be collected during a routine geriatric consultation. During this consultation, the scores of comorbidities (CIRS), autonomy (ADL and IADL) and frailty (CFS) will be collected. An assessment of physical performance will be carried out by measuring the Short Physical Performance Battery (SPPBS) and the "Handgrip". If it is impossible to carry out the consultation (patient unable to move), the follow-up data (CIRS, ADL and CFS) will be collected from the patient or his relatives during a phone interview conducted by a clinical research technician.

Conditions

Elderly Patient (80 Years Old or More) Admitted to Intensive Care

Keywords

neopterin

Outcome Measures

Primary Outcomes (1)

• Survival without significant loss of autonomy

  Autonomy is evaluated by Activities of Daily Living score (ADL). This score is based on a 6-item questionnaire. Each item is rated 0, 0.5 or 1. 1 is the best outcome. A significant loss of autonomy is defined by a ADL score at 3 month after inclusion lower by more than 1 point compared to the ADL score before hospitalization.

  Month 3

Secondary Outcomes (6)

• Intra-hospital mortality

  Month 3

• Mortality

  Month 3

• Functional autonomy

  Month 3

• Short Physical Performance Battery

  Month 3

• Handgrip test

  Month 3

Other Outcomes (3)

• Simplified Acute Physiology Score III (SAPS3)

  Day 0

• Clinical Frailty Scale (CFS)

  Day 0

• Cumulative Illness Rating Scale (CIRS)

  Day 0

Interventions

Blood sample OTHER

Dosage of neopterin

Eligibility Criteria

• Age: 80 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The population is selected from 80-year-old patients or more attending intensive care unit for less than 24 hours.

You may qualify if:

• Age ≥ 80 years old
• Admission to intensive care unit before 24 hours

You may not qualify if:

• Hospitalisation for a scheduled surgery
• New admission within a month before previous stay to intensive care unit
• Active solid cancer or malignant hemopathy
• Immunosuppressant treatment (including corticotherapy \> 5 mg/d)
• Autoimmune disease
• Tutorship or curatorship

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead
• Institut National de la Santé Et de la Recherche Médicale, France: collaborator

Study Sites (1)

Hôpital Saint-Antoine / Service de réanimation

Paris, 75012, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood sample

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Hélène VALLET, MD

  Hôpital Saint-Antoine - APHP

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hélène VALLET, MD

CONTACT

01 49 28 20 42; helene.vallet@aphp.fr

Bertrand GUIDET, MD

CONTACT

01 71 97 01 21; bertrand.guidet@aphp.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2022
• First Posted: February 10, 2022
• Study Start: November 21, 2022
• Primary Completion: August 1, 2025
• Study Completion: August 1, 2025
• Last Updated: February 17, 2025

Record last verified: 2025-02

Locations

FR (1)